RCM
DMIIU

Rivernorth Capital Management’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Rivernorth Capital Management’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400,000
Closed -$4.01M – 635
2025
Q4 		$4.01M Hold
400,000
– – 0.19% 174
2025
Q3 		$3.98M Buy
+400,000
New +$3.99M 0.23% 128

Other funds holding DMIIU

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Rivernorth Capital Management's DMIIU Position: Q1 2026 in Review

Rivernorth Capital Management sold out of Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q1 2026, closing a stake of 400,000 shares — an estimated $4.01M sold.

Rivernorth Capital Management first reported a position in DMIIU in Q3 2025 and held it in 2 quarters. The position peaked at $4.01M in Q4 2025. 14 funds tracked by Wall St. Rank hold DMIIU as of Q1 2026.

  • Rivernorth Capital Management reported no remaining Drugs Made In America Acquisition II Corp Unit position as of Q1 2026 after selling out during the quarter.
  • Rivernorth Capital Management sold 400,000 Drugs Made In America Acquisition II Corp Unit shares in Q1 2026, an estimated $4.01M.
  • Rivernorth Capital Management first reported a position in Drugs Made In America Acquisition II Corp Unit in Q3 2025 and held it in 2 quarters.
  • Rivernorth Capital Management's Drugs Made In America Acquisition II Corp Unit position peaked at $4.01M in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q1 2026.

Based on Rivernorth Capital Management's 13F filing for Q1 2026, filed 15 May 2026.